ArticleJournal of Cancer2019
The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection.
Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-institutional Retrospective Study.In vivo (Athens, Greece)Trial
- Stromal secreted protein acidic and rich in cysteine expression: A potential target for improved prognosis in patients with pancreatic cancer.World journal of gastrointestinal oncology · 2025Article
- In situ chemoimmunotherapy hydrogel elicits immunogenic cell death and evokes efficient antitumor immune response.Journal of translational medicine · 2024Article
- Prognostic significance of SPARC expression in non-small cell lung cancer: A meta-analysis and bioinformatics analysis.Oncology letters · 2022Article
- The identification of liver metastasis- and prognosis-associated genes in pancreatic ductal adenocarcinoma.BMC cancer · 2022Article
- GPRC5A: An emerging prognostic biomarker for predicting malignancy of Pancreatic Cancer based on bioinformatics analysis.Journal of Cancer · 2021Article
- Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma.Practical laboratory medicine · 2020Article
- Pathogenesis and Treatment of Pancreatic Cancer Related Pain.Anticancer research · 2020Review
- Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma.Disease markers · 2020Article
- Temporal trends of incidence and mortality in Asian-Americans with pancreatic adenocarcinoma: an epidemiological study.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.